PGlu-3-methyl-His-Pro-NH2 (TFA)

PGlu-3-methyl-His-Pro-NH2 TFA (A-42872 TFA), the modified thyrotropin-releasing hormone (TRH) peptide, enhances binding to pituitary TRH receptors and increases stimulation of thyroid-stimulating hormone (TSH) release from the pituitary. The in vitro permeability of PGlu-3-methyl-His-Pro-NH2 TFA through rat skin is increased in the presence of enhancers Ethanol and Cineole[1][2].

Product Specifications

Product Name Alternative

A-42872 (TFA)

UNSPSC

12352209

Target

Others

Type

Peptides

Related Pathways

Others

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/pglu-3-methyl-his-pro-nh2-tfa.html

Purity

99.69

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 250 mg/mL (ultrasonic)

Smiles

CN1C(C[C@H](NC([C@@H](N2)CCC2=O)=O)C(N3[C@@H](CCC3)C(N)=O)=O)=CN=C1.OC(C(F)(F)F)=O

Molecular Formula

C19H25F3N6O6

Molecular Weight

490.43

References & Citations

[1]Koskinen LO, et al. Cerebrovascular effects of the TRH analogues pGlu-3-methyl-His-Pro amide and pGlu-Glu-Pro amide: a comparison with TRH. Ups J Med Sci. 2000;105 (1) :73-83.|[2]Magnusson BM, et al. Biological effects after percutaneous absorption of thyrotropin-releasing hormone and its analogue M-TRH. Peptides. 2001 Jan;22 (1) :73-9.